Dr. Kerry Rogers is an assistant professor in the Division of Hematology at The Ohio State University and specializes in chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Dr. Rogers earned her BA from Northwestern University and MD from the Chicago Medical School. She completed her residency in Internal Medicine at University of Michigan and fellowship in Hematology and Medical Oncology at OSU where she is currently a faculty member. Dr. Rogers is board certified in Internal Medicine as well as both Hematology and Medical Oncology. In addition to caring for patients with CLL and HCL in clinic, she is the principal investigator on several clinical trials studying chemotherapy-free combination regimens for CLL utilizing currently approved or novel agents. The group at OSU has lead the development of ibrutinib (Imbruvica) as well as other BTK inhibitors and pioneered research into its effects on the immune environment and molecular mechanisms of resistance. Dr. Rogers is also a part of the active HCL research group at OSU. Her other clinical research interests include complications of targeted therapy for CLL, management of Richter’s syndrome, and primary and CLL-associated autoimmune cytopenias. Dr. Rogers conducts laboratory research in autoimmune hemolytic anemia.